Trials / Terminated
TerminatedNCT00408018
Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Piramal Enterprises Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
P276-00 is a molecule derived from Rohitukine, which through pre clinical assays was identified as a selective Cdk4-D1 and Cdk1-B inhibitor.The inhibition of these Cdks causes cell cycle arrest between the G1-S transition thus blocking the cell cycle events at an early stage of development. It therefore has the potential for being efficacious with lesser side effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | P276-00 | Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2008-08-01
- Completion
- 2008-10-01
- First posted
- 2006-12-05
- Last updated
- 2009-01-01
Locations
3 sites across 1 country: India
Source: ClinicalTrials.gov record NCT00408018. Inclusion in this directory is not an endorsement.